JPS6344749B2 - - Google Patents
Info
- Publication number
- JPS6344749B2 JPS6344749B2 JP53037029A JP3702978A JPS6344749B2 JP S6344749 B2 JPS6344749 B2 JP S6344749B2 JP 53037029 A JP53037029 A JP 53037029A JP 3702978 A JP3702978 A JP 3702978A JP S6344749 B2 JPS6344749 B2 JP S6344749B2
- Authority
- JP
- Japan
- Prior art keywords
- piperazinyl
- formula
- phenylquinoline
- physiologically acceptable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000001430 anti-depressive effect Effects 0.000 claims description 9
- 239000000935 antidepressant agent Substances 0.000 claims description 8
- 229940005513 antidepressants Drugs 0.000 claims description 8
- LYLBRVQNLFMNLN-UHFFFAOYSA-N 4-phenyl-2-piperazin-1-ylquinoline Chemical class C1CNCCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 LYLBRVQNLFMNLN-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- PHOZLMDTTWWBAH-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)-4-phenylquinoline Chemical group C1CN(CC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 PHOZLMDTTWWBAH-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000002075 main ingredient Substances 0.000 claims description 2
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 claims 4
- RZBGGQIZFRGGGX-UHFFFAOYSA-N 4-phenyl-2-(4-propylpiperazin-1-yl)quinoline Chemical compound C1CN(CCC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 RZBGGQIZFRGGGX-UHFFFAOYSA-N 0.000 claims 2
- CGNNDGGDQIYZHU-UHFFFAOYSA-N 2-(4-butylpiperazin-1-yl)-4-phenylquinoline Chemical group C1CN(CCCC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 CGNNDGGDQIYZHU-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 12
- 229960004801 imipramine Drugs 0.000 description 11
- -1 inorganic acid salts Chemical class 0.000 description 10
- 230000006742 locomotor activity Effects 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229960005333 tetrabenazine Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000009132 Catalepsy Diseases 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010047853 Waxy flexibility Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229960001252 methamphetamine Drugs 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- 206010015995 Eyelid ptosis Diseases 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000003004 ptosis Diseases 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- YEKLOAJGHZTNED-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)-4-phenylquinoline;dihydrochloride Chemical compound Cl.Cl.C1CN(CC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 YEKLOAJGHZTNED-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 230000008503 anti depressant like effect Effects 0.000 description 3
- 230000000891 anti-reserpine Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- JHVUPPWRYKEKSW-SPIKMXEPSA-N (Z)-but-2-enedioic acid 2-(4-butylpiperazin-1-yl)-4-phenylquinoline Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(CCCC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 JHVUPPWRYKEKSW-SPIKMXEPSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OBMBUODDCOAJQP-UHFFFAOYSA-N 2-chloro-4-phenylquinoline Chemical compound C=12C=CC=CC2=NC(Cl)=CC=1C1=CC=CC=C1 OBMBUODDCOAJQP-UHFFFAOYSA-N 0.000 description 2
- AOZWXJICERQHHW-UHFFFAOYSA-N 4-phenyl-2-(4-propylpiperazin-1-yl)quinoline;dihydrochloride Chemical compound Cl.Cl.C1CN(CCC)CCN1C1=CC(C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 AOZWXJICERQHHW-UHFFFAOYSA-N 0.000 description 2
- ZPXUXYIRQHODJU-UHFFFAOYSA-N 6-chloro-4-phenyl-2-(4-phenylpiperazin-1-yl)quinoline Chemical compound C12=CC(Cl)=CC=C2N=C(N2CCN(CC2)C=2C=CC=CC=2)C=C1C1=CC=CC=C1 ZPXUXYIRQHODJU-UHFFFAOYSA-N 0.000 description 2
- 208000004130 Blepharoptosis Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- WUFPNASKMLJSND-UHFFFAOYSA-N 3-methoxy-4-hydroxyphenylethyleneglycol sulfate Chemical compound COC1=CC(C(O)CO)=CC=C1OS(O)(=O)=O WUFPNASKMLJSND-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- PTRMVVJMLDKZBI-UHFFFAOYSA-N 6-chloro-2-(4-methylpiperazin-1-yl)-4-phenylquinoline Chemical compound C1CN(C)CCN1C1=CC(C=2C=CC=CC=2)=C(C=C(Cl)C=C2)C2=N1 PTRMVVJMLDKZBI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003470 muricidal effect Effects 0.000 description 1
- 239000003773 muricide Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãäžè¬åŒïŒïŒ
ïŒåŒäžãã¯ççŽ ååæ°ïŒãïŒã®äœçŽã¢ã«ãã«
åºãŸãã¯ã¢ãªã«åºãæå³ãããïŒ ã§è¡šããããïŒâïŒïŒâããã©ãžãã«ïŒâïŒâã
ãšãã«ãããªã³èªå°äœãŸãã¯ãã®çççã«èš±å®¹ã
ããå¡©é¡ãäž»æåãšããæãã€å€ã«é¢ããã åŒïŒïŒã§è¡šããããååç©ã®çççã«èš±å®¹ã
ããå¡©é¡ãšããŠã¯ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ããšãŠ
åæ°ŽçŽ é žå¡©ãç¡«é žå¡©ããªã³é žå¡©çã®ç¡æ©é žå¡©ãã
ãã³ã¯ãšã³é žå¡©ããã¬ã€ã³é žå¡©ãããã«é žå¡©ãé
ç³é žå¡©ãå®æ¯éŠé žå¡©ãä¹³é žå¡©ãã¡ã¿ã³ã¹ã«ãã³é ž
å¡©çã®ææ©é žå¡©ãæããããããããã®å¡©é¡ã¯æ°Ž
åç©ã®åœ¢ã§ååšããããšãããã®ã§ããããã®æ°Ž
åç©ããŸãæ¬çºæã®ååç©ã«å å«ãããã åŒïŒïŒã«ãããäœçŽã¢ã«ãã«åºãšããŠã¯ãäŸ
ãã°ãšãã«åºãïœâãããã«åºãïœâããã«åºã
æããããã åŒïŒïŒã§è¡šããããååç©ã¯æç®æªèŒã®æ°èŠ
ååç©ã§ããã ç±³åœç¹èš±ç¬¬3542785å·ããã³ç¬¬3668207å·ã«ã¯ã
äžè¬åŒïŒïŒ ïŒåŒäžãPhã¯ïŒïŒïŒâããšãã¬ã³åºãæå³ãã
R1ã¯æ°ŽçŽ ååãã¢ããåºãŸãã¯èèªæçåæ°ŽçŽ
åºãæå³ããR2ã¯èèªæçåæ°ŽçŽ åºãŸãã¯è³éŠ
âèèªæçåæ°ŽçŽ åºãæå³ããR3ã¯æ°ŽçŽ ååã
èèªæåºãè³éŠâèèªæåºãŸãã¯è³éŠæåºãæå³
ããR4ã¯ççŽ ç°åŒãŸãã¯è€çŽ ç°åŒã®åç°åŒãŸã
ã¯äºç°åŒè³éŠæåºãæå³ãããïŒ ãé瀺ãããŠãããåŒïŒïŒã§è¡šããããååç©
ã¯ãæŠå¿µçã«ã¯åŒïŒïŒã®äžã«å«ãŸããã ããããäžèšç±³åœç¹èš±ã«ã¯ãåŒïŒïŒã§è¡šãã
ããååç©ã¯å ·äœçã«ã¯é瀺ãããŠãããåŒ
ïŒïŒã«é¡äŒŒããæ§é ãæããååç©ãšããŠã¯ã
ãããã«åŒïŒïŒ ïŒåŒäžãR1ã¯ã¡ãã«åºãŸãã¯ããšãã«åºãæ
å³ãããïŒ ã§è¡šããããïŒâã¯ããâïŒâïŒïŒâã¡ãã«âïŒ
âããã©ãžãã«ïŒâïŒâããšãã«ãããªã³ããã³
ïŒâã¯ããâïŒâïŒïŒâããšãã«âïŒâããã©ãž
ãã«ïŒâïŒâããšãã«ãããªã³ãèŠåºãããã«ã
ããªããããããåŒïŒïŒããã³åŒïŒïŒã§è¡šã
ãããååç©ã®è¬å¹ãšããŠã¯ãæççããã³å©å°¿
äœçšãèšèŒãããŠããã«ãããããããã®äœçšã¯
æ¬çºæã®äž»é¡ã§ããæãã€äœçšãšã¯å šãç°ãªãã
ã®ã§ãããæŽã«ãåŸèšã®å®éšçµæããæãããªã
ãã«ãåŒïŒïŒã§è¡šããããååç©ã®è¬çå¹æ
ã¯ãåŒïŒïŒã§è¡šããããå ¬ç¥ã®é¡äŒŒååç©ã®ã
ãã«æ¯ã¹ãŠã¯ããã«åªãããã®ã§ããã ãŸããHelv.Chim.Acta 60ïŒ1644â1649
ïŒ1977ïŒã«ã¯ãåŒïŒïŒã«ãããŠïŒ²ãã¡ãã«åºã§
ããååç©ãèšèŒãããŠããããè¬çäœçšã«ã€ã
ãŠã¯äœãèšåãããŠããªãã æ¬çºæè ãã¯ãåªããäžæ¢ç¥çµç³»è¬å€ãèŠåºã
ã¹ãéæç 究ãéããçµæãåŒïŒïŒã§è¡šããã
ãååç©ããã³ãã®çççã«èš±å®¹ãããå¡©é¡ãåª
ããè¬çäœçšãæããããšãèŠåºããæ¬çºæãå®
æããã åŒïŒïŒã§è¡šããããååç©ããã³ãã®å¡©é¡
ã¯ãåç©å®éšã«ãããŠãæã¬ã»ã«ãã³äœçšïŒäœæž©
äžéããã³ã«ã¿ã¬ãã·ãŒã«å¯Ÿããæ®æäœçšïŒãæ
ããã©ãããžã³äœçšïŒçŒçŒäžåã«å¯Ÿããæ®æäœ
çšïŒãå çç Žå£ã©ããã®ãã¿æ®ºããïŒmuricideïŒ
æå¶äœçšãããã¯ãã«ã¢ãã¬ããªã³ã®ä»£è¬å転
ïŒturnoverïŒæå¶äœçšçã®äžç°ç³»æãã€å€ã«ç¹æ
ã®è¬çäœçšïŒä»¥äžãæãã€å€æ§äœçšãšèšãïŒãæ
ããæãã€å€ãšããŠæçšã§ããããã®äœçšã®ç¹åŸŽ
ã¯ãæãã€å€æ§äœçšã匷åã§ããã°ããã§ãªãã
äžç°ç³»æãã€å€ã§ã¯ã»ãšãã©èªããããªãèªçºé
åæå¶äœçšãæã¡ã¿ã³ããšã¿ãã³äœçšãããã¯ã
ãŒããã³ã®ä»£è¬å転亢é²äœçšçã®ç²Ÿç¥åè£ç æ²»ç
å€æ§ã®äžæ¢æå¶äœçšããæããç¹ã«ããã ãŸããåŒïŒïŒã«ãããŠïŒ²ããšãã«åºã§ããå
åç©ãåããšããããã€ãã®ååç©ããã³ãã®å¡©
é¡ã¯ãæãã¬ã¢ãªã³äœçšãæããæããŒãã³ãœã³
å€ãšããŠãæçšã§ããã 以äžã«ãæ¬çºæã®ä»£è¡šçååç©ãå ¬ç¥ã®é¡äŒŒå
åç©ããã³åžè²©ã®è¬å€ã«ã€ããŠã®è¬çå®éšã®çµæ
ã瀺ããæ¬çºæã®ååç©ã®è¬çäœçšã«ã€ããŠèª¬æ
ãããED50ã¯LitchfieldâWilcoxonæ³ã«ããç®
åºãããã®ã§ããããªãå®éšã«äœ¿çšããååç©ã¯
以äžã®éãã§ããã ïŒæ¬çºæã®ååç©ïŒ ïŒïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ã»ãžå¡©é žå¡© ïŒïŒâïŒïœâããã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡© ïŒå¯Ÿç §ååç©ïŒ ïŒïŒïŒâã¯ããâïŒâïŒïŒâã¡ãã«âïŒâããã©
ãžãã«ïŒâïŒâããšãã«ãããªã³ã»ãžå¡©é žå¡©
ïŒç±³åœç¹èš±ç¬¬3542785å·ããã³ç¬¬3668207å·ïŒ ïŒïŒïŒâã¯ããâïŒâïŒïŒâããšãã«âïŒâãã
ã©ãžãã«ïŒâïŒâããšãã«ãããªã³ïŒç±³åœç¹èš±
第3542785å·ããã³ç¬¬3668207å·ïŒ ïŒïŒã€ããã©ãã³ïŒåžè²©ã®äžç°ç³»æãã€å€ïŒ ïŒïŒã¯ãã«ããããžã³ïŒåžè²©ã®ç²Ÿç¥åè£ç æ²»ç
å€ïŒ (1) æã¬ã»ã«ãã³äœçš ïœ äœæž©äžéã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
ïŒå¹ãçšããB.M.Askewã®æ¹æ³ãLife Sci.ïŒïŒ
725ïŒ1963ïŒãã«æºããŠãããªã€ããã¬ã»ã«ãã³ïŒ
mgïŒKgã®è ¹è å æäžãšåæã«è©Šéšååç©ã®ïŒçšé
ãçµå£æäžããïŒæéåŸã«ãµãŒãã¹ã¿ãŒæž©åºŠèš
ïŒè浊é»æ°BMGâ130ïŒãçšããŠçŽè žæž©ã枬å®
ãããã¬ã»ã«ãã³ã«ããçŽè žæž©ã®äžéã50ïŒ æå¶
ããçšéïŒED50ïŒãç®åºããã ïœ ã«ã¿ã¬ãã·ãŒã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããã¬ã»ã«ãã³ïŒmgïŒKgã®è ¹è å æäž
ïŒæéåŸã«è©Šéšååç©ã®ïŒçšéãçµå£æäžããïŒ
æéåŸã«ã«ã¿ã¬ãã·ãŒã枬å®ãããã¬ã»ã«ãã³ã«
ããæ¹èµ·ãããã«ã¿ã¬ãã·ãŒã®åºçŸã50ïŒ ãè¡šã ã®ããŠã¹ã«ãããŠæå¶ãããçšéïŒED50ïŒãç®
åºããã ïœããã³ïœã®å®éšçµæãè¡šïŒã«ç€ºããè¡šïŒã«ç€º
ãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢ã®æã¬ã»ã«
ãã³äœçšã¯ã€ããã©ãã³ã®ããããã匷ããç¹ã«
ååç©ïŒ¡ã®äœçšã匷ããäœæž©äžéããã³ã«ã¿ã¬ã
ã·ãŒã«å¯Ÿããæ®æäœçšã®å¹åã¯ãããããã€ãã
ã©ãã³ã®3.7åããã³25.5åã§ããã äžæ¹ãé¡äŒŒååç©ïŒã«ã¯äœçšãèªããããããŸ
ãé¡äŒŒååç©ïŒã®å¹åã¯ãæ¬çºæã®ååç©ã®çŽ1/
ïŒã1/13ã«ãããªãã (2) èªçºéåæå¶äœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
ïŒå¹ãçšãããè©Šéšååç©ã®ïŒçšéãçµå£æäž
ããïŒæéåŸã«Animexéåé枬å®è£ 眮
ïŒFarad瀟補ïŒãçšããŠïŒåéã«ãããèªçºéå
ã枬å®ãããççé£å¡©æ°Žæäžå¯Ÿç §çŸ€ãšæ¯ã¹ãŠèªçº
éåéã50ïŒ æå¶ããçšéïŒED50ïŒãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢
ã¯ãã¯ãã«ããããžã³ã®çŽ1/7ã1/8ã®åŒ·ãã®èªçº
éåæå¶äœçšãæãããäžæ¹ãé¡äŒŒååç©ïŒãã
ãŒïŒäžŠã³ã«ã€ããã©ãã³ã¯èªçºéåæå¶äœçšã瀺
ããªãã (3) ãã®ä»ã®æãã€å€æ§äœçš ïœ ããã©ãããžã³çŒçŒäžåã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããè©Šéšååç©ã®ïŒçšéãçµå£æäž
ããïŒæéåŸã«ããã©ãããžã³70mgïŒKgãè ¹è å
æäžãããããã©ãããžã³æäžïŒæéåŸã«ãP.
A.J.Janssenãã®æ¹æ³ãArzneim.Forsch.15ïŒ104
ïŒ1965ïŒãã«æºããŠçŒçŒäžåã®çšåºŠãïŒæ®µéïŒã¹ã³
ã¢ïŒïŒå®å šéçŒãïŒïŒ1/4éçŒãïŒïŒ1/2éçŒã
ïŒïŒ3/4éçŒãïŒïŒå®å šéçŒïŒã§å€å®ããããã
ã©ãããžã³ã«ããçŒçŒäžåã50ïŒ æå¶ããçšé
ïŒED50ïŒãç®åºããã ïœ å çç Žå£ã©ããã®ãã¿æ®ºãæå¶äœçš Z.P.Horovitzãã®æ¹æ³ãInt.J.
Neuropharmacol.ïŒïŒ405ïŒ1966ïŒãã«æºããŠå ç
ãç Žå£ããããšã«ãã€ãŠäœè£œããããã¿æ®ºãäœå
ã®åœ¢æãããSTDâãŠã€ã¹ã¿ãŒç³»éæ§ã©ãã
ïŒäœé240ã260ïœïŒïŒçŸ€15å¹ãçšãããè©Šéšåå
ç©ã®ïŒçšéãè ¹è å æäžããïŒæéåŸã«ãã¿æ®ºã
è¡åã®åºçŸã®æç¡ã調ã¹ãåºçŸçã50ïŒ æå¶ãã
çšéïŒED50ïŒãç®åºããã ïœããã³ïœã®å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯ãã€ã
ãã©ãã³ã®çŽ2.7åã®åŒ·ãã®æããã©ãããžã³äœ
çšããã³ã€ããã©ãã³ãšåçšåºŠã®ãã¿æ®ºãæå¶äœ
çšãæããã (4) æã¡ã¿ã³ããšã¿ãã³äœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããã¡ã¿ã³ããšã¿ãã³ïŒmgïŒKgãè ¹è
å æäžããã®30ååŸã«è©Šéšååç©ã®ïŒçšéãè ¹è
å æäžããã¡ã¿ã³ããšã¿ãã³æäžïŒæéåŸã«
Animexéåé枬å®è£ 眮ãçšããŠ10åéã«ãã
ãèªçºéåã枬å®ãããã¡ã¿ã³ããšã¿ãã³ã«ãã
èªçºãããèªçºéåã®å¢å ã50ïŒ æå¶ããçšé
ïŒED50ïŒãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢
ã¯ãã¯ãã«ããããžã³ã®çŽ1/8ã1/16ã®åŒ·ãã®æ
ã¡ã¿ã³ããšã¿ãã³äœçšãæãããäžæ¹ãã€ããã©
ãã³ã¯äœçšã瀺ããªãã (5) ã¢ãã¢ãã³ä»£è¬ç©ã«åãŒãäœçš äœé160ã180ïœã®STDâãŠã€ã¹ã¿ãŒç³»éæ§ã©
ããïŒçŸ€ïŒå¹ãçšãããè©Šéšååç©ã®100mgïŒKg
ãçµå£æäžããïŒïŒïŒïŒïŒæéåŸã®è³å ãã¢ãã
ãªã³é žïŒä»¥äžHVAãšèšãïŒãïŒâã¡ããã·âïŒ
âããããã·ããšãã«ãšãã¬ã³ã°ãªã³ãŒã« ã¹ã«
ããšãŒãïŒä»¥äžMOPEGâSO4ãšèšãïŒããã³ïŒ
âããããã·ã€ã³ããŒã«é ¢é žïŒä»¥äžïŒâHIAAãš
èšãïŒãå®éããã HVAããã³ïŒâHIAAã®å®éã¯åæ²¢ãã®æ¹æ³
ãLife Sci.15ïŒ1465ïŒ1974ïŒãããŸãMOPEGâSO4
ã®å®éã¯J.L.Meekãã®æ¹æ³ãBr.J.Pharmacol.
45ïŒ435ïŒ1972ïŒãã«æºããŠãããªã€ããã¢ãã¢ã
ã³ä»£è¬ç©ã®å€ã¯ãïŒïœæ¹¿ééåœãã®éãšããŠç®åº
ããåŸãå¯Ÿç §çŸ€ã«å¯ŸããçŸåçã§è¡šç€ºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯HVA
ã®èããå¢å ãæ¹èµ·ããããŒããã³ã®ä»£è¬å転亢
é²äœçšã瀺åããããäžæ¹ãã€ããã©ãã³ã§ã¯ã
ã®äœçšãèªããããªãã æŽã«ãååç©ïŒ¢ã¯MOPEGâSO4ãææã«æžå°
ãããã€ããã©ãã³ãšåæ§ã«ãã«ã¢ãã¬ããªã³ã®
代è¬å転æå¶äœçšã瀺åãããã ããããªãããååç©ïŒ¡ã¯ãã€ããã©ãã³ãšç°
ãªããã»ãããã³ã®ä»£è¬å転æå¶äœçšã瀺ããª
ãã (6) æ¥æ§æ¯æ§ äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããè©Šéšååç©ã®ïŒãïŒçšéãçµå£ã
ããã¯è ¹è å æäžããïŒæ¥éã«ãããæ»äº¡ã®æç¡
ã芳ç¥ãããããããæ³ã«ããLD50ãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯ãã€ã
ãã©ãã³ãšåçšåºŠãªãã幟å匱ãæ¯æ§ãæããã äžèšå®éšçµæããæãããªããã«ãåŒïŒïŒã§
è¡šããããååç©ããã³ãã®å¡©é¡ã¯ã匷åãªæã
ã€å€æ§äœçšãæããã°ããã§ãªããã€ããã©ãã³
ãããã¯ç±³åœç¹èš±ç¬¬3542785å·çã«é瀺ãããŠã
ãé¡äŒŒååç©ã«ã¯èªããããªãã粟ç¥åè£ç æ²»ç
å€æ§ã®äžæ¢æå¶äœçšããæãããã€æ¯æ§ã匱ãã®
ã§ãæãã€å€ãšããŠãã€ç ãããã¯ãã€ç¶æ ã®æ²»
çã«äœ¿çšããããšãã§ãããç¹ã«ãäžå®ãçŠèºæ
ã䌎ããã€ç ãããã¯ãã€ç¶æ ã«æå¹ãšèããã
ãããã®æäžåœ¢æ ãšããŠã¯çµå£æäžãããã¯éçµ
å£æäžã®ãããã§ããããåŒïŒïŒã§è¡šãããã
ååç©ãŸãã¯ãã®å¡©é¡ã®æäžéã¯ãååç©ã®çš®
é¡ãæäžæ¹æ³ãçç¶ã幎什çã«ããç°ãªãããé
åžž0.2ãïŒmgïŒKgïŒæ¥ã§ããã åŒïŒïŒã§è¡šããããååç©ãŸãã¯ãã®å¡©é¡
ã¯ãéåžžã補å€çšæ äœãšæ··åããŠèª¿è£œãã補å€ã®
圢ã§é©çšãããã補å€çšæ äœãšããŠã¯ã補å€åé
ã«ãããŠåžžçšããããã€åŒïŒïŒã§è¡šããããå
åç©ãŸãã¯ãã®å¡©é¡ãšåå¿ããªãç©è³ªãäŸãã°ãŒ
ã©ãã³ãä¹³ç³ãçœç³ãé žåãã¿ã³ããã³ãã³ãçµ
æ¶ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãã
ãªãŠã ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ã«ã«ã·ãŠ
ã ãããããã·ãããã«ã»ã«ããŒã¹ãããããã·
ãããã«ã¡ãã«ã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ã
ãœã«ãããŒã«ããœã«ãã¿ã³èèªé žãšã¹ãã«ãããª
ããã«ãããªãã³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ã
軜質ç¡æ°Žã±ã€é žãã¿ã«ã¯ãæ€ç©æ²¹ããã³ãžã«ã¢ã«
ã³ãŒã«ãã¢ã©ãã¢ãŽã ããããã¬ã³ã°ãªã³ãŒã«ã
ããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«ãæããããã補å€ãš
ããŠã¯ãé å€ãã«ãã»ã«å€ãé¡ç²å€ãæ£å€ãåå€
çã®åºäœè£œå€ããŸãã¯ã·ãããå€ããšãªãã·ã«
å€ã泚å°å€çã®æ¶²äœè£œå€ãæããããããããã®
補å€ã¯åžžæ³ã«åŸã€ãŠèª¿è£œãããããªã液äœè£œå€ã«
ãã€ãŠã¯ãçšæãæ°ŽãŸãã¯ä»ã®é©åœãªåªäœã«æº¶è§£
ãŸãã¯æžæ¿ããã圢ã§ãã€ãŠãããããŸãé å€ã¯
åšç¥ã®æ¹æ³ã§ã³ãŒãã€ã³ã°ããŠãããã泚å°å€ã®
å Žåã«ã¯ãéåžžãåŒïŒïŒã§è¡šããããååç©ã
é žä»å å¡©ã®åœ¢ã§æ°Žã«æº¶è§£ãããŠçšããããå¿ èŠã«
å¿ããŠççé£å¡©æ°Žãããã¯ãããŠç³æº¶æ¶²ã«æº¶è§£ã
ããŠãããããŸãç·©è¡å€ãä¿åå€ãæ·»å ããŠãã
ãã ãããã®è£œå€ã¯ããã®çš®é¡çã«ããç°ãªããã
éåžžã掻æ§æåãšããŠãåŒïŒïŒã§è¡šããããå
åç©ãŸãã¯ãã®å¡©é¡ã0.5ïŒ ä»¥äžã奜ãŸããã¯ïŒ
ã60ïŒ ã®å²åã§å«æããããšãã§ããããããã®
補å€ã¯ãŸããæ²»çäžæå¹ãªä»ã®ååç©ãå«æããŠ
ããŠãããã åŒïŒïŒã§è¡šããããååç©ã¯ãç±³åœç¹èš±ç¬¬
3542785å·ãå第3668207å·ïŒHelv.Chim.Acta
60ïŒ1644â1649ïŒ1977ïŒçã«èšèŒãããæ¹æ³ã«æº
ããŠè£œé ããããšãã§ããã äŸãã°ã(a)äžè¬åŒïŒïŒ ïŒåŒäžãã¯ããã²ã³ååãŸãã¯äœçŽã¢ã«ãã«
ããªåºãæå³ãããïŒ ã§è¡šããããååç©ãšäžè¬åŒïŒïŒ ïŒåŒäžãã¯åæ²ã«åããã®ãæå³ãããïŒ ã§è¡šããããããã©ãžã³é¡ãšãåå¿ããããããŸ
ãã¯(b)äžè¬åŒïŒïŒã§è¡šããããååç©ãšããã©
ãžã³ãšãåå¿ãããŠãïŒâããšãã«âïŒâïŒïŒâ
ããã©ãžãã«ïŒãããªã³ãåŸã次ãã§è©²ååç©ãš
äžè¬åŒïŒïŒ â ïŒïŒ ïŒåŒäžãã¯åæ²ã«åããã®ãæå³ããã¯ã¢
ã«ã³ãŒã«ã®åå¿æ§ãšã¹ãã«æ®åºãæå³ãããïŒ ã§è¡šããããã¢ã«ãã«åå€ãšãåå¿ãããããšã«
ãããåŒïŒïŒã§è¡šããããååç©ãåŸãããšã
ã§ããã (a)ããã³(b)æ³ãåå¿åŒã§ç€ºãã°æ¬¡ã®éãã§ã
ãã ïŒåŒäžãïŒïŒžããã³ïŒ¹ã¯åæ²ã«åããã®ãæ
å³ãããïŒ ä»¥äžã«(a)æ³ããã³(b)æ³ã«ã€ããŠè©³çŽ°ã«èª¬æã
ãã (a)æ³ã«ãããŠïŒ åŒïŒïŒã«ãããŠïŒžã§è¡šããããããã²ã³åå
ãšããŠã¯ãå¡©çŽ ååãèçŽ ååãããŸã奜ãŸãã
äœçŽã¢ã«ãã«ããªåºãšããŠã¯ãã¡ãã«ããªåºãæ
ããããã åŒïŒïŒã§è¡šããããååç©ãšããã©ãžã³é¡
ïŒïŒãšã®åå¿ã¯ãéåžžãäžæŽ»æ§æº¶åªäžã§è¡ããã
äžæŽ»æ§æº¶åªãšããŠã¯ãäŸãã°ãã«ãšã³ããã·ã¬ã³
çã®è³éŠæçåæ°ŽçŽ é¡ãã¡ãã«ãšãã«ã±ãã³çã®
äœçŽã¢ã«ã«ãã³é¡ããžãªããµã³ããžã°ã©ã€ã çã®
ãšãŒãã«é¡ããžã¡ãã«ãã«ã ã¢ããããžã¡ãã«ã¹
ã«ããã·ããæãããããæ¬åå¿ã¯å¡©åºã®ååšäž
ã«è¡ãã®ã奜ãŸããããããã©ãžã³é¡ïŒïŒãé
å°ãçšããŠãããå ŒããããŠããããå¡©åºãšããŠ
ã¯ãäŸãã°çé žãããªãŠã ãçé žã«ãªãŠã çã®ç
é žã¢ã«ã«ãªãçé žæ°ŽçŽ ãããªãŠã ãçé žæ°ŽçŽ ã«ãª
ãŠã çã®çé žæ°ŽçŽ ã¢ã«ã«ãªãããªãšãã«ã¢ãã³ç
ã®ç¬¬ïŒã¢ãã³ãæãããããããã©ãžã³é¡ïŒïŒ
ã¯å¡©é žå¡©ãç¡«é žå¡©çã®å¡©ã®åœ¢ã§äœ¿çšããŠãããã
åå¿æž©åºŠãšããŠã¯100ãã140âã®ç¯å²ã奜ãŸããã (b)æ³ã«ã€ããŠïŒ åŒïŒïŒã«ãããŠïŒ¹ã§è¡šããããã¢ã«ã³ãŒã«ã®
åå¿æ§ãšã¹ãã«æ®åºãšããŠã¯ãäŸãã°å¡©çŽ ååã
èçŽ ååããšãŠçŽ ååã®ãããªããã²ã³ååãäœ
çŽã¢ã«ã³ãã·ã¹ã«ããã«ãªãã·åºããã³ãŒã³ã¹ã«
ããã«ãªãã·åºãïœâãã«ãšã³ã¹ã«ããã«ãªãã·
åºã®ãããªã¢ãªãŒã«ã¹ã«ããã«ãªãã·åºãæãã
ãããã¢ã«ãã«åå€ïŒïŒã®å ·äœäŸãšããŠã¯ããš
ãŠåãšãã«ããšãŠåãããã«ããšãŠåããã«ãå¡©
åã¢ãªã«ããžãšãã«ç¡«é žãïœâãã«ãšã³ã¹ã«ãã³
é žãšãã«ãšã¹ãã«çãæããããã åŒïŒïŒã§è¡šããããååç©ãšããã©ãžã³ãšã®
åå¿ã¯ã(a)æ³ãšåæ§ã®åå¿æ¡ä»¶äžã«è¡ãããšãã§
ããããªããããã©ãžã³ã¯æ°Žåç©ãããã¯å¡©ã®åœ¢
ã§äœ¿çšããŠãããã ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³ãšã¢ã«ãã«åå€ïŒïŒãšã®åå¿ã¯ãéåžžãäž
掻æ§æº¶åªäžã§è¡ãããäžæŽ»æ§æº¶åªãšããŠã¯ãäŸã
ã°ãã³ãŒã³ããã«ãšã³ããã·ã¬ã³çã®è³éŠæçå
æ°ŽçŽ é¡ãã¡ãã«ãšãã«ã±ãã³çã®äœçŽã¢ã«ã«ãã³
é¡ããžãªããµã³çã®ãšãŒãã«é¡ããžã¡ãã«ãã«ã
ã¢ãããæãããããæ¬åå¿ã¯å¡©åºã®ååšäžã«è¡
ãã®ã奜ãŸãããå¡©åºã®å ·äœäŸãšããŠã¯ã(a)æ³ã®
éšåã§è¿°ã¹ãå¡©åºã®å ·äœäŸããã®ãŸãŸæããããš
ãã§ãããåå¿æž©åºŠãšããŠã¯70ãã160âã®ç¯å²ã
奜ãŸããã åŒïŒïŒã«ãããŠïŒžãããã²ã³ååã§ããåæ
ååç©ã¯ãæç®èšèŒã®æ¹æ³ãJ.Am.Chem.Soc.
70ïŒ2402â2404ïŒ1948ïŒã«åŸã€ãŠå®¹æã«åŸãããã
ãŸãããäœçŽã¢ã«ãã«ããªåºã§ããååç©ã¯ã
äŸãã°äžèšã®æ¹æ³ã«åŸã€ãŠåŸãããã äžèšå補æ³ã«ããçæããååç©ã¯ãåžžæ³ã«åŸ
ã€ãŠåé¢ã粟補ãããã åŒïŒïŒã§è¡šããããååç©ã¯ãåæååç©ã®
éžå®ãåå¿ã»åŠçæ¡ä»¶çã«ãããéé¢å¡©åºããã
ã¯å¡©ããŸãã¯æ°Žåç©ã®åœ¢ã§åŸããããå¡©ã¯ãåžž
æ³ãäŸãã°æ°Žé žåã¢ã«ã«ãªã®ãããªå¡©åºã§åŠçã
ãããšã«ãããéé¢å¡©åºã«å€ããããšãã§ããã
äžæ¹ãéé¢å¡©åºã¯ãåžžæ³ã«åŸã€ãŠçççã«èš±å®¹ã
ããåçš®ã®é žãšåŠçããããšã«ãããå¡©ã«å°ãã
ãšãã§ããã 以äžã«å®æœäŸãæããŠæ¬çºæãæŽã«å ·äœçã«èª¬
æããããæ¬çºæã¯ãããå®æœäŸã«éå®ãããã
ã®ã§ã¯ãªãããªããååç©ã®åå®ã¯å çŽ åæå€ã
ãã¹ã»ã¹ãã¯ãã«ãIRã¹ãã¯ãã«ãNMRã¹ãã¯
ãã«çã«ãããããªã€ãã å®æœäŸ ïŒ é å€ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžå¡©é žå¡© âŠâŠïŒïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ33ïœ ä¹³ ç³ âŠâŠ75ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ30ïœ ããããã·ãããã«ã»ã«ããŒã¹ âŠâŠïŒïœ 軜質ç¡æ°Žã±ã€é ž âŠâŠïŒïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠïŒïœ åžžæ³ã«åŸã€ãŠãäžèšåæåãæ··åããé¡ç²ç¶ãš
ããå§çž®æåããŠïŒé 150mgã®é è¯1000é ã調補
ããã次ãã§ãããããã·ãããã«ã¡ãã«ã»ã«ã
ãŒã¹ãã¿ã«ã¯ãé žåãã¿ã³ããã³ãœã«ãã¿ã³èèª
é žãšã¹ãã«ãçšããåžžæ³ã«åŸã€ãŠå€ç®ãæœããã€
ã«ã ã³ãŒãã€ã³ã°é ãšããã å®æœäŸ ïŒ ã«ãã»ã«å€ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžå¡©é žå¡© âŠâŠ10ïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ49ïœ ä¹³ ç³ âŠâŠ15ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ25ïœ ã¿ã«ã¯ âŠâŠ0.5ïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠ0.5ïœ åžžæ³ã«åŸã€ãŠãäžèšåæåãæ··åããé¡ç²ç¶ãš
ãããã®ãã«ãã»ã«1000åã«å ãŠãããïŒå100
mgã®ã«ãã»ã«å€ã調補ããã å®æœäŸ ïŒ é å€ ïŒâïŒïŒâïœâããã«âïŒâããã©ãžãã«ïŒâ
ïŒâããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©
âŠâŠ10ïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ27ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ40ïœ ããããã·ãããã«ã»ã«ããŒã¹ âŠâŠ20ïœ è»œè³ªç¡æ°Žã±ã€é ž âŠâŠïŒïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠïŒïœ äžèšåæåãæ··åããçŽæ¥æé æ³ã«ããå§çž®æ
åããŠïŒé 100mgã®é è¯1000é ã調補ããã次ã
ã§ãããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ãã¿ã«
ã¯ãé žåãã¿ã³ããã³ãœã«ãã¿ã³èèªé žãšã¹ãã«
ãçšããåžžæ³ã«åŸã€ãŠå€ç®ãæœããã€ã«ã ã³ãŒã
ã€ã³ã°é ãšããã å®æœäŸ ïŒ ïŒâããšãã«âïŒâïŒïŒâïœâãããã«âïŒâ
ããã©ãžãã«ïŒãããªã³ã»ãžå¡©é žå¡©ãŸãã¯ïŒâ
ïŒïŒâã¢ãªã«âïŒâããã©ãžãã«ïŒâïŒâããšã
ã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©ãçšããå®æœäŸïŒïŒ
ïŒãŸãã¯ïŒãšåæ§ã«åŠçããŠãé å€ãŸãã¯ã«ãã»
ã«å€ãåŸãã å®æœäŸ ïŒ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ ïŒâã¯ããâïŒâããšãã«ãããªã³2.0ïœãã
ã³ïŒâãšãã«ããã©ãžã³2.7ïœããã«ãšã³15mlã«
å ãã10æéå ç±éæµããããå·åŸãæ°Žãå ãã
é ¢é žãšãã«ã§æœåºããææ©å±€ãç¡æ°Žç¡«é žãããªãŠ
ã ã§ä¹Ÿç¥ããã溶åªãæžå§äžã«çå»ããæ®æž£ãã¯
ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«25ïœãçšããŠ
ã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ããæåã«æº¶åºã
ãéšåãæšãŠãç¶ããŠæº¶åºããéšåãéããŠç®ç
ç©2.3ïœïŒïŒåç87ïŒ ïŒãåŸããèç¹ 87ã88â ãã®éé¢å¡©åºããšã¿ããŒã«æ§å¡©é žã§åŠçããŠå¡©
é žå¡©ãšãªãããšã¿ããŒã«ããåçµæ¶ããŠç®çç©ã®
ãžå¡©é žå¡©ãåŸããèç¹ 225ã230â å®æœäŸ ïŒ ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³ ïŒâã¯ããâïŒâããšãã«ãããªã³4.0ïœãã
ã³ç¡æ°Žããã©ãžã³8.0ïœããã«ãšã³ïŒmlã«å ãã
ïŒæéå ç±éæµããããå·åŸãæ°Žãå ããé ¢é žãš
ãã«ã§æœåºããææ©å±€ãæ°ŽæŽãç¡æ°Žç¡«é žãããªãŠ
ã ã§ä¹Ÿç¥ããã溶åªãæžå§äžã«çå»ããæ®æž£ãã¯
ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«40ïœãçšããŠ
ã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ããæåã«æº¶åºã
ãéšåãæšãŠãç¶ããŠæº¶åºããéšåãéãããšãŒ
ãã«ããåçµæ¶ããŠç®çç©4.4ïœïŒåç92ïŒ ïŒã
åŸããèç¹ 133ã134â å®æœäŸ ïŒ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³3.0ïœããšãŠåãšãã«1.9ïœããã³çé žãããª
ãŠã 1.1ïœãã¡ãã«ãšãã«ã±ãã³30mlã«å ããæ¹
æäž12æéå ç±éæµãããã次ãã§æžå§äžã«æ¿çž®
ããæ®æž£ã«æ°Žãå ããé ¢é žãšãã«ã§æœåºããææ©
å±€ãç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããã溶åªã®çå»
åŸãæ®æž£ãã¯ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«
30ïœãçšããŠã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ãã
æåã«æº¶åºããéšåãéããŠç®çç©2.8ïœïŒåç
85ïŒ ïŒãåŸãã èç¹ 87ã88â å®æœäŸïŒïŒïŒãšåæ§ã«åå¿ã»åŠçããŠæ¬¡ã®åå
ç©ãåŸãã ïŒâããšãã«âïŒâïŒïŒâïœâãããã«âïŒâ
ããã©ãžãã«ïŒãããªã³ã»ãžå¡©é žå¡© èç¹ 225ã230â ïŒâïŒïŒâïœâããã«âïŒâããã©ãžãã«ïŒâ
ïŒâããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡© èç¹ 167ã168â ïŒâïŒïŒâã¢ãªã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©èç¹ 179ã
181âã
åºãŸãã¯ã¢ãªã«åºãæå³ãããïŒ ã§è¡šããããïŒâïŒïŒâããã©ãžãã«ïŒâïŒâã
ãšãã«ãããªã³èªå°äœãŸãã¯ãã®çççã«èš±å®¹ã
ããå¡©é¡ãäž»æåãšããæãã€å€ã«é¢ããã åŒïŒïŒã§è¡šããããååç©ã®çççã«èš±å®¹ã
ããå¡©é¡ãšããŠã¯ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ããšãŠ
åæ°ŽçŽ é žå¡©ãç¡«é žå¡©ããªã³é žå¡©çã®ç¡æ©é žå¡©ãã
ãã³ã¯ãšã³é žå¡©ããã¬ã€ã³é žå¡©ãããã«é žå¡©ãé
ç³é žå¡©ãå®æ¯éŠé žå¡©ãä¹³é žå¡©ãã¡ã¿ã³ã¹ã«ãã³é ž
å¡©çã®ææ©é žå¡©ãæããããããããã®å¡©é¡ã¯æ°Ž
åç©ã®åœ¢ã§ååšããããšãããã®ã§ããããã®æ°Ž
åç©ããŸãæ¬çºæã®ååç©ã«å å«ãããã åŒïŒïŒã«ãããäœçŽã¢ã«ãã«åºãšããŠã¯ãäŸ
ãã°ãšãã«åºãïœâãããã«åºãïœâããã«åºã
æããããã åŒïŒïŒã§è¡šããããååç©ã¯æç®æªèŒã®æ°èŠ
ååç©ã§ããã ç±³åœç¹èš±ç¬¬3542785å·ããã³ç¬¬3668207å·ã«ã¯ã
äžè¬åŒïŒïŒ ïŒåŒäžãPhã¯ïŒïŒïŒâããšãã¬ã³åºãæå³ãã
R1ã¯æ°ŽçŽ ååãã¢ããåºãŸãã¯èèªæçåæ°ŽçŽ
åºãæå³ããR2ã¯èèªæçåæ°ŽçŽ åºãŸãã¯è³éŠ
âèèªæçåæ°ŽçŽ åºãæå³ããR3ã¯æ°ŽçŽ ååã
èèªæåºãè³éŠâèèªæåºãŸãã¯è³éŠæåºãæå³
ããR4ã¯ççŽ ç°åŒãŸãã¯è€çŽ ç°åŒã®åç°åŒãŸã
ã¯äºç°åŒè³éŠæåºãæå³ãããïŒ ãé瀺ãããŠãããåŒïŒïŒã§è¡šããããååç©
ã¯ãæŠå¿µçã«ã¯åŒïŒïŒã®äžã«å«ãŸããã ããããäžèšç±³åœç¹èš±ã«ã¯ãåŒïŒïŒã§è¡šãã
ããååç©ã¯å ·äœçã«ã¯é瀺ãããŠãããåŒ
ïŒïŒã«é¡äŒŒããæ§é ãæããååç©ãšããŠã¯ã
ãããã«åŒïŒïŒ ïŒåŒäžãR1ã¯ã¡ãã«åºãŸãã¯ããšãã«åºãæ
å³ãããïŒ ã§è¡šããããïŒâã¯ããâïŒâïŒïŒâã¡ãã«âïŒ
âããã©ãžãã«ïŒâïŒâããšãã«ãããªã³ããã³
ïŒâã¯ããâïŒâïŒïŒâããšãã«âïŒâããã©ãž
ãã«ïŒâïŒâããšãã«ãããªã³ãèŠåºãããã«ã
ããªããããããåŒïŒïŒããã³åŒïŒïŒã§è¡šã
ãããååç©ã®è¬å¹ãšããŠã¯ãæççããã³å©å°¿
äœçšãèšèŒãããŠããã«ãããããããã®äœçšã¯
æ¬çºæã®äž»é¡ã§ããæãã€äœçšãšã¯å šãç°ãªãã
ã®ã§ãããæŽã«ãåŸèšã®å®éšçµæããæãããªã
ãã«ãåŒïŒïŒã§è¡šããããååç©ã®è¬çå¹æ
ã¯ãåŒïŒïŒã§è¡šããããå ¬ç¥ã®é¡äŒŒååç©ã®ã
ãã«æ¯ã¹ãŠã¯ããã«åªãããã®ã§ããã ãŸããHelv.Chim.Acta 60ïŒ1644â1649
ïŒ1977ïŒã«ã¯ãåŒïŒïŒã«ãããŠïŒ²ãã¡ãã«åºã§
ããååç©ãèšèŒãããŠããããè¬çäœçšã«ã€ã
ãŠã¯äœãèšåãããŠããªãã æ¬çºæè ãã¯ãåªããäžæ¢ç¥çµç³»è¬å€ãèŠåºã
ã¹ãéæç 究ãéããçµæãåŒïŒïŒã§è¡šããã
ãååç©ããã³ãã®çççã«èš±å®¹ãããå¡©é¡ãåª
ããè¬çäœçšãæããããšãèŠåºããæ¬çºæãå®
æããã åŒïŒïŒã§è¡šããããååç©ããã³ãã®å¡©é¡
ã¯ãåç©å®éšã«ãããŠãæã¬ã»ã«ãã³äœçšïŒäœæž©
äžéããã³ã«ã¿ã¬ãã·ãŒã«å¯Ÿããæ®æäœçšïŒãæ
ããã©ãããžã³äœçšïŒçŒçŒäžåã«å¯Ÿããæ®æäœ
çšïŒãå çç Žå£ã©ããã®ãã¿æ®ºããïŒmuricideïŒ
æå¶äœçšãããã¯ãã«ã¢ãã¬ããªã³ã®ä»£è¬å転
ïŒturnoverïŒæå¶äœçšçã®äžç°ç³»æãã€å€ã«ç¹æ
ã®è¬çäœçšïŒä»¥äžãæãã€å€æ§äœçšãšèšãïŒãæ
ããæãã€å€ãšããŠæçšã§ããããã®äœçšã®ç¹åŸŽ
ã¯ãæãã€å€æ§äœçšã匷åã§ããã°ããã§ãªãã
äžç°ç³»æãã€å€ã§ã¯ã»ãšãã©èªããããªãèªçºé
åæå¶äœçšãæã¡ã¿ã³ããšã¿ãã³äœçšãããã¯ã
ãŒããã³ã®ä»£è¬å転亢é²äœçšçã®ç²Ÿç¥åè£ç æ²»ç
å€æ§ã®äžæ¢æå¶äœçšããæããç¹ã«ããã ãŸããåŒïŒïŒã«ãããŠïŒ²ããšãã«åºã§ããå
åç©ãåããšããããã€ãã®ååç©ããã³ãã®å¡©
é¡ã¯ãæãã¬ã¢ãªã³äœçšãæããæããŒãã³ãœã³
å€ãšããŠãæçšã§ããã 以äžã«ãæ¬çºæã®ä»£è¡šçååç©ãå ¬ç¥ã®é¡äŒŒå
åç©ããã³åžè²©ã®è¬å€ã«ã€ããŠã®è¬çå®éšã®çµæ
ã瀺ããæ¬çºæã®ååç©ã®è¬çäœçšã«ã€ããŠèª¬æ
ãããED50ã¯LitchfieldâWilcoxonæ³ã«ããç®
åºãããã®ã§ããããªãå®éšã«äœ¿çšããååç©ã¯
以äžã®éãã§ããã ïŒæ¬çºæã®ååç©ïŒ ïŒïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ã»ãžå¡©é žå¡© ïŒïŒâïŒïœâããã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡© ïŒå¯Ÿç §ååç©ïŒ ïŒïŒïŒâã¯ããâïŒâïŒïŒâã¡ãã«âïŒâããã©
ãžãã«ïŒâïŒâããšãã«ãããªã³ã»ãžå¡©é žå¡©
ïŒç±³åœç¹èš±ç¬¬3542785å·ããã³ç¬¬3668207å·ïŒ ïŒïŒïŒâã¯ããâïŒâïŒïŒâããšãã«âïŒâãã
ã©ãžãã«ïŒâïŒâããšãã«ãããªã³ïŒç±³åœç¹èš±
第3542785å·ããã³ç¬¬3668207å·ïŒ ïŒïŒã€ããã©ãã³ïŒåžè²©ã®äžç°ç³»æãã€å€ïŒ ïŒïŒã¯ãã«ããããžã³ïŒåžè²©ã®ç²Ÿç¥åè£ç æ²»ç
å€ïŒ (1) æã¬ã»ã«ãã³äœçš ïœ äœæž©äžéã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
ïŒå¹ãçšããB.M.Askewã®æ¹æ³ãLife Sci.ïŒïŒ
725ïŒ1963ïŒãã«æºããŠãããªã€ããã¬ã»ã«ãã³ïŒ
mgïŒKgã®è ¹è å æäžãšåæã«è©Šéšååç©ã®ïŒçšé
ãçµå£æäžããïŒæéåŸã«ãµãŒãã¹ã¿ãŒæž©åºŠèš
ïŒè浊é»æ°BMGâ130ïŒãçšããŠçŽè žæž©ã枬å®
ãããã¬ã»ã«ãã³ã«ããçŽè žæž©ã®äžéã50ïŒ æå¶
ããçšéïŒED50ïŒãç®åºããã ïœ ã«ã¿ã¬ãã·ãŒã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããã¬ã»ã«ãã³ïŒmgïŒKgã®è ¹è å æäž
ïŒæéåŸã«è©Šéšååç©ã®ïŒçšéãçµå£æäžããïŒ
æéåŸã«ã«ã¿ã¬ãã·ãŒã枬å®ãããã¬ã»ã«ãã³ã«
ããæ¹èµ·ãããã«ã¿ã¬ãã·ãŒã®åºçŸã50ïŒ ãè¡šã ã®ããŠã¹ã«ãããŠæå¶ãããçšéïŒED50ïŒãç®
åºããã ïœããã³ïœã®å®éšçµæãè¡šïŒã«ç€ºããè¡šïŒã«ç€º
ãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢ã®æã¬ã»ã«
ãã³äœçšã¯ã€ããã©ãã³ã®ããããã匷ããç¹ã«
ååç©ïŒ¡ã®äœçšã匷ããäœæž©äžéããã³ã«ã¿ã¬ã
ã·ãŒã«å¯Ÿããæ®æäœçšã®å¹åã¯ãããããã€ãã
ã©ãã³ã®3.7åããã³25.5åã§ããã äžæ¹ãé¡äŒŒååç©ïŒã«ã¯äœçšãèªããããããŸ
ãé¡äŒŒååç©ïŒã®å¹åã¯ãæ¬çºæã®ååç©ã®çŽ1/
ïŒã1/13ã«ãããªãã (2) èªçºéåæå¶äœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
ïŒå¹ãçšãããè©Šéšååç©ã®ïŒçšéãçµå£æäž
ããïŒæéåŸã«Animexéåé枬å®è£ 眮
ïŒFarad瀟補ïŒãçšããŠïŒåéã«ãããèªçºéå
ã枬å®ãããççé£å¡©æ°Žæäžå¯Ÿç §çŸ€ãšæ¯ã¹ãŠèªçº
éåéã50ïŒ æå¶ããçšéïŒED50ïŒãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢
ã¯ãã¯ãã«ããããžã³ã®çŽ1/7ã1/8ã®åŒ·ãã®èªçº
éåæå¶äœçšãæãããäžæ¹ãé¡äŒŒååç©ïŒãã
ãŒïŒäžŠã³ã«ã€ããã©ãã³ã¯èªçºéåæå¶äœçšã瀺
ããªãã (3) ãã®ä»ã®æãã€å€æ§äœçš ïœ ããã©ãããžã³çŒçŒäžåã«å¯Ÿããæ®æäœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããè©Šéšååç©ã®ïŒçšéãçµå£æäž
ããïŒæéåŸã«ããã©ãããžã³70mgïŒKgãè ¹è å
æäžãããããã©ãããžã³æäžïŒæéåŸã«ãP.
A.J.Janssenãã®æ¹æ³ãArzneim.Forsch.15ïŒ104
ïŒ1965ïŒãã«æºããŠçŒçŒäžåã®çšåºŠãïŒæ®µéïŒã¹ã³
ã¢ïŒïŒå®å šéçŒãïŒïŒ1/4éçŒãïŒïŒ1/2éçŒã
ïŒïŒ3/4éçŒãïŒïŒå®å šéçŒïŒã§å€å®ããããã
ã©ãããžã³ã«ããçŒçŒäžåã50ïŒ æå¶ããçšé
ïŒED50ïŒãç®åºããã ïœ å çç Žå£ã©ããã®ãã¿æ®ºãæå¶äœçš Z.P.Horovitzãã®æ¹æ³ãInt.J.
Neuropharmacol.ïŒïŒ405ïŒ1966ïŒãã«æºããŠå ç
ãç Žå£ããããšã«ãã€ãŠäœè£œããããã¿æ®ºãäœå
ã®åœ¢æãããSTDâãŠã€ã¹ã¿ãŒç³»éæ§ã©ãã
ïŒäœé240ã260ïœïŒïŒçŸ€15å¹ãçšãããè©Šéšåå
ç©ã®ïŒçšéãè ¹è å æäžããïŒæéåŸã«ãã¿æ®ºã
è¡åã®åºçŸã®æç¡ã調ã¹ãåºçŸçã50ïŒ æå¶ãã
çšéïŒED50ïŒãç®åºããã ïœããã³ïœã®å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯ãã€ã
ãã©ãã³ã®çŽ2.7åã®åŒ·ãã®æããã©ãããžã³äœ
çšããã³ã€ããã©ãã³ãšåçšåºŠã®ãã¿æ®ºãæå¶äœ
çšãæããã (4) æã¡ã¿ã³ããšã¿ãã³äœçš äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããã¡ã¿ã³ããšã¿ãã³ïŒmgïŒKgãè ¹è
å æäžããã®30ååŸã«è©Šéšååç©ã®ïŒçšéãè ¹è
å æäžããã¡ã¿ã³ããšã¿ãã³æäžïŒæéåŸã«
Animexéåé枬å®è£ 眮ãçšããŠ10åéã«ãã
ãèªçºéåã枬å®ãããã¡ã¿ã³ããšã¿ãã³ã«ãã
èªçºãããèªçºéåã®å¢å ã50ïŒ æå¶ããçšé
ïŒED50ïŒãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ããã³ïŒ¢
ã¯ãã¯ãã«ããããžã³ã®çŽ1/8ã1/16ã®åŒ·ãã®æ
ã¡ã¿ã³ããšã¿ãã³äœçšãæãããäžæ¹ãã€ããã©
ãã³ã¯äœçšã瀺ããªãã (5) ã¢ãã¢ãã³ä»£è¬ç©ã«åãŒãäœçš äœé160ã180ïœã®STDâãŠã€ã¹ã¿ãŒç³»éæ§ã©
ããïŒçŸ€ïŒå¹ãçšãããè©Šéšååç©ã®100mgïŒKg
ãçµå£æäžããïŒïŒïŒïŒïŒæéåŸã®è³å ãã¢ãã
ãªã³é žïŒä»¥äžHVAãšèšãïŒãïŒâã¡ããã·âïŒ
âããããã·ããšãã«ãšãã¬ã³ã°ãªã³ãŒã« ã¹ã«
ããšãŒãïŒä»¥äžMOPEGâSO4ãšèšãïŒããã³ïŒ
âããããã·ã€ã³ããŒã«é ¢é žïŒä»¥äžïŒâHIAAãš
èšãïŒãå®éããã HVAããã³ïŒâHIAAã®å®éã¯åæ²¢ãã®æ¹æ³
ãLife Sci.15ïŒ1465ïŒ1974ïŒãããŸãMOPEGâSO4
ã®å®éã¯J.L.Meekãã®æ¹æ³ãBr.J.Pharmacol.
45ïŒ435ïŒ1972ïŒãã«æºããŠãããªã€ããã¢ãã¢ã
ã³ä»£è¬ç©ã®å€ã¯ãïŒïœæ¹¿ééåœãã®éãšããŠç®åº
ããåŸãå¯Ÿç §çŸ€ã«å¯ŸããçŸåçã§è¡šç€ºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯HVA
ã®èããå¢å ãæ¹èµ·ããããŒããã³ã®ä»£è¬å転亢
é²äœçšã瀺åããããäžæ¹ãã€ããã©ãã³ã§ã¯ã
ã®äœçšãèªããããªãã æŽã«ãååç©ïŒ¢ã¯MOPEGâSO4ãææã«æžå°
ãããã€ããã©ãã³ãšåæ§ã«ãã«ã¢ãã¬ããªã³ã®
代è¬å転æå¶äœçšã瀺åãããã ããããªãããååç©ïŒ¡ã¯ãã€ããã©ãã³ãšç°
ãªããã»ãããã³ã®ä»£è¬å転æå¶äœçšã瀺ããª
ãã (6) æ¥æ§æ¯æ§ äœé20ã25ïœã®STDâddYç³»éæ§ããŠã¹ïŒçŸ€
10å¹ãçšãããè©Šéšååç©ã®ïŒãïŒçšéãçµå£ã
ããã¯è ¹è å æäžããïŒæ¥éã«ãããæ»äº¡ã®æç¡
ã芳ç¥ãããããããæ³ã«ããLD50ãç®åºããã å®éšçµæãè¡šïŒã«ç€ºãã ãè¡šã è¡šïŒã«ç€ºãããã«ãæ¬çºæã®ååç©ïŒ¡ã¯ãã€ã
ãã©ãã³ãšåçšåºŠãªãã幟å匱ãæ¯æ§ãæããã äžèšå®éšçµæããæãããªããã«ãåŒïŒïŒã§
è¡šããããååç©ããã³ãã®å¡©é¡ã¯ã匷åãªæã
ã€å€æ§äœçšãæããã°ããã§ãªããã€ããã©ãã³
ãããã¯ç±³åœç¹èš±ç¬¬3542785å·çã«é瀺ãããŠã
ãé¡äŒŒååç©ã«ã¯èªããããªãã粟ç¥åè£ç æ²»ç
å€æ§ã®äžæ¢æå¶äœçšããæãããã€æ¯æ§ã匱ãã®
ã§ãæãã€å€ãšããŠãã€ç ãããã¯ãã€ç¶æ ã®æ²»
çã«äœ¿çšããããšãã§ãããç¹ã«ãäžå®ãçŠèºæ
ã䌎ããã€ç ãããã¯ãã€ç¶æ ã«æå¹ãšèããã
ãããã®æäžåœ¢æ ãšããŠã¯çµå£æäžãããã¯éçµ
å£æäžã®ãããã§ããããåŒïŒïŒã§è¡šãããã
ååç©ãŸãã¯ãã®å¡©é¡ã®æäžéã¯ãååç©ã®çš®
é¡ãæäžæ¹æ³ãçç¶ã幎什çã«ããç°ãªãããé
åžž0.2ãïŒmgïŒKgïŒæ¥ã§ããã åŒïŒïŒã§è¡šããããååç©ãŸãã¯ãã®å¡©é¡
ã¯ãéåžžã補å€çšæ äœãšæ··åããŠèª¿è£œãã補å€ã®
圢ã§é©çšãããã補å€çšæ äœãšããŠã¯ã補å€åé
ã«ãããŠåžžçšããããã€åŒïŒïŒã§è¡šããããå
åç©ãŸãã¯ãã®å¡©é¡ãšåå¿ããªãç©è³ªãäŸãã°ãŒ
ã©ãã³ãä¹³ç³ãçœç³ãé žåãã¿ã³ããã³ãã³ãçµ
æ¶ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãã
ãªãŠã ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ã«ã«ã·ãŠ
ã ãããããã·ãããã«ã»ã«ããŒã¹ãããããã·
ãããã«ã¡ãã«ã»ã«ããŒã¹ãã¡ãã«ã»ã«ããŒã¹ã
ãœã«ãããŒã«ããœã«ãã¿ã³èèªé žãšã¹ãã«ãããª
ããã«ãããªãã³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ã
軜質ç¡æ°Žã±ã€é žãã¿ã«ã¯ãæ€ç©æ²¹ããã³ãžã«ã¢ã«
ã³ãŒã«ãã¢ã©ãã¢ãŽã ããããã¬ã³ã°ãªã³ãŒã«ã
ããªã¢ã«ãã¬ã³ã°ãªã³ãŒã«ãæããããã補å€ãš
ããŠã¯ãé å€ãã«ãã»ã«å€ãé¡ç²å€ãæ£å€ãåå€
çã®åºäœè£œå€ããŸãã¯ã·ãããå€ããšãªãã·ã«
å€ã泚å°å€çã®æ¶²äœè£œå€ãæããããããããã®
補å€ã¯åžžæ³ã«åŸã€ãŠèª¿è£œãããããªã液äœè£œå€ã«
ãã€ãŠã¯ãçšæãæ°ŽãŸãã¯ä»ã®é©åœãªåªäœã«æº¶è§£
ãŸãã¯æžæ¿ããã圢ã§ãã€ãŠãããããŸãé å€ã¯
åšç¥ã®æ¹æ³ã§ã³ãŒãã€ã³ã°ããŠãããã泚å°å€ã®
å Žåã«ã¯ãéåžžãåŒïŒïŒã§è¡šããããååç©ã
é žä»å å¡©ã®åœ¢ã§æ°Žã«æº¶è§£ãããŠçšããããå¿ èŠã«
å¿ããŠççé£å¡©æ°Žãããã¯ãããŠç³æº¶æ¶²ã«æº¶è§£ã
ããŠãããããŸãç·©è¡å€ãä¿åå€ãæ·»å ããŠãã
ãã ãããã®è£œå€ã¯ããã®çš®é¡çã«ããç°ãªããã
éåžžã掻æ§æåãšããŠãåŒïŒïŒã§è¡šããããå
åç©ãŸãã¯ãã®å¡©é¡ã0.5ïŒ ä»¥äžã奜ãŸããã¯ïŒ
ã60ïŒ ã®å²åã§å«æããããšãã§ããããããã®
補å€ã¯ãŸããæ²»çäžæå¹ãªä»ã®ååç©ãå«æããŠ
ããŠãããã åŒïŒïŒã§è¡šããããååç©ã¯ãç±³åœç¹èš±ç¬¬
3542785å·ãå第3668207å·ïŒHelv.Chim.Acta
60ïŒ1644â1649ïŒ1977ïŒçã«èšèŒãããæ¹æ³ã«æº
ããŠè£œé ããããšãã§ããã äŸãã°ã(a)äžè¬åŒïŒïŒ ïŒåŒäžãã¯ããã²ã³ååãŸãã¯äœçŽã¢ã«ãã«
ããªåºãæå³ãããïŒ ã§è¡šããããååç©ãšäžè¬åŒïŒïŒ ïŒåŒäžãã¯åæ²ã«åããã®ãæå³ãããïŒ ã§è¡šããããããã©ãžã³é¡ãšãåå¿ããããããŸ
ãã¯(b)äžè¬åŒïŒïŒã§è¡šããããååç©ãšããã©
ãžã³ãšãåå¿ãããŠãïŒâããšãã«âïŒâïŒïŒâ
ããã©ãžãã«ïŒãããªã³ãåŸã次ãã§è©²ååç©ãš
äžè¬åŒïŒïŒ â ïŒïŒ ïŒåŒäžãã¯åæ²ã«åããã®ãæå³ããã¯ã¢
ã«ã³ãŒã«ã®åå¿æ§ãšã¹ãã«æ®åºãæå³ãããïŒ ã§è¡šããããã¢ã«ãã«åå€ãšãåå¿ãããããšã«
ãããåŒïŒïŒã§è¡šããããååç©ãåŸãããšã
ã§ããã (a)ããã³(b)æ³ãåå¿åŒã§ç€ºãã°æ¬¡ã®éãã§ã
ãã ïŒåŒäžãïŒïŒžããã³ïŒ¹ã¯åæ²ã«åããã®ãæ
å³ãããïŒ ä»¥äžã«(a)æ³ããã³(b)æ³ã«ã€ããŠè©³çŽ°ã«èª¬æã
ãã (a)æ³ã«ãããŠïŒ åŒïŒïŒã«ãããŠïŒžã§è¡šããããããã²ã³åå
ãšããŠã¯ãå¡©çŽ ååãèçŽ ååãããŸã奜ãŸãã
äœçŽã¢ã«ãã«ããªåºãšããŠã¯ãã¡ãã«ããªåºãæ
ããããã åŒïŒïŒã§è¡šããããååç©ãšããã©ãžã³é¡
ïŒïŒãšã®åå¿ã¯ãéåžžãäžæŽ»æ§æº¶åªäžã§è¡ããã
äžæŽ»æ§æº¶åªãšããŠã¯ãäŸãã°ãã«ãšã³ããã·ã¬ã³
çã®è³éŠæçåæ°ŽçŽ é¡ãã¡ãã«ãšãã«ã±ãã³çã®
äœçŽã¢ã«ã«ãã³é¡ããžãªããµã³ããžã°ã©ã€ã çã®
ãšãŒãã«é¡ããžã¡ãã«ãã«ã ã¢ããããžã¡ãã«ã¹
ã«ããã·ããæãããããæ¬åå¿ã¯å¡©åºã®ååšäž
ã«è¡ãã®ã奜ãŸããããããã©ãžã³é¡ïŒïŒãé
å°ãçšããŠãããå ŒããããŠããããå¡©åºãšããŠ
ã¯ãäŸãã°çé žãããªãŠã ãçé žã«ãªãŠã çã®ç
é žã¢ã«ã«ãªãçé žæ°ŽçŽ ãããªãŠã ãçé žæ°ŽçŽ ã«ãª
ãŠã çã®çé žæ°ŽçŽ ã¢ã«ã«ãªãããªãšãã«ã¢ãã³ç
ã®ç¬¬ïŒã¢ãã³ãæãããããããã©ãžã³é¡ïŒïŒ
ã¯å¡©é žå¡©ãç¡«é žå¡©çã®å¡©ã®åœ¢ã§äœ¿çšããŠãããã
åå¿æž©åºŠãšããŠã¯100ãã140âã®ç¯å²ã奜ãŸããã (b)æ³ã«ã€ããŠïŒ åŒïŒïŒã«ãããŠïŒ¹ã§è¡šããããã¢ã«ã³ãŒã«ã®
åå¿æ§ãšã¹ãã«æ®åºãšããŠã¯ãäŸãã°å¡©çŽ ååã
èçŽ ååããšãŠçŽ ååã®ãããªããã²ã³ååãäœ
çŽã¢ã«ã³ãã·ã¹ã«ããã«ãªãã·åºããã³ãŒã³ã¹ã«
ããã«ãªãã·åºãïœâãã«ãšã³ã¹ã«ããã«ãªãã·
åºã®ãããªã¢ãªãŒã«ã¹ã«ããã«ãªãã·åºãæãã
ãããã¢ã«ãã«åå€ïŒïŒã®å ·äœäŸãšããŠã¯ããš
ãŠåãšãã«ããšãŠåãããã«ããšãŠåããã«ãå¡©
åã¢ãªã«ããžãšãã«ç¡«é žãïœâãã«ãšã³ã¹ã«ãã³
é žãšãã«ãšã¹ãã«çãæããããã åŒïŒïŒã§è¡šããããååç©ãšããã©ãžã³ãšã®
åå¿ã¯ã(a)æ³ãšåæ§ã®åå¿æ¡ä»¶äžã«è¡ãããšãã§
ããããªããããã©ãžã³ã¯æ°Žåç©ãããã¯å¡©ã®åœ¢
ã§äœ¿çšããŠãããã ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³ãšã¢ã«ãã«åå€ïŒïŒãšã®åå¿ã¯ãéåžžãäž
掻æ§æº¶åªäžã§è¡ãããäžæŽ»æ§æº¶åªãšããŠã¯ãäŸã
ã°ãã³ãŒã³ããã«ãšã³ããã·ã¬ã³çã®è³éŠæçå
æ°ŽçŽ é¡ãã¡ãã«ãšãã«ã±ãã³çã®äœçŽã¢ã«ã«ãã³
é¡ããžãªããµã³çã®ãšãŒãã«é¡ããžã¡ãã«ãã«ã
ã¢ãããæãããããæ¬åå¿ã¯å¡©åºã®ååšäžã«è¡
ãã®ã奜ãŸãããå¡©åºã®å ·äœäŸãšããŠã¯ã(a)æ³ã®
éšåã§è¿°ã¹ãå¡©åºã®å ·äœäŸããã®ãŸãŸæããããš
ãã§ãããåå¿æž©åºŠãšããŠã¯70ãã160âã®ç¯å²ã
奜ãŸããã åŒïŒïŒã«ãããŠïŒžãããã²ã³ååã§ããåæ
ååç©ã¯ãæç®èšèŒã®æ¹æ³ãJ.Am.Chem.Soc.
70ïŒ2402â2404ïŒ1948ïŒã«åŸã€ãŠå®¹æã«åŸãããã
ãŸãããäœçŽã¢ã«ãã«ããªåºã§ããååç©ã¯ã
äŸãã°äžèšã®æ¹æ³ã«åŸã€ãŠåŸãããã äžèšå補æ³ã«ããçæããååç©ã¯ãåžžæ³ã«åŸ
ã€ãŠåé¢ã粟補ãããã åŒïŒïŒã§è¡šããããååç©ã¯ãåæååç©ã®
éžå®ãåå¿ã»åŠçæ¡ä»¶çã«ãããéé¢å¡©åºããã
ã¯å¡©ããŸãã¯æ°Žåç©ã®åœ¢ã§åŸããããå¡©ã¯ãåžž
æ³ãäŸãã°æ°Žé žåã¢ã«ã«ãªã®ãããªå¡©åºã§åŠçã
ãããšã«ãããéé¢å¡©åºã«å€ããããšãã§ããã
äžæ¹ãéé¢å¡©åºã¯ãåžžæ³ã«åŸã€ãŠçççã«èš±å®¹ã
ããåçš®ã®é žãšåŠçããããšã«ãããå¡©ã«å°ãã
ãšãã§ããã 以äžã«å®æœäŸãæããŠæ¬çºæãæŽã«å ·äœçã«èª¬
æããããæ¬çºæã¯ãããå®æœäŸã«éå®ãããã
ã®ã§ã¯ãªãããªããååç©ã®åå®ã¯å çŽ åæå€ã
ãã¹ã»ã¹ãã¯ãã«ãIRã¹ãã¯ãã«ãNMRã¹ãã¯
ãã«çã«ãããããªã€ãã å®æœäŸ ïŒ é å€ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžå¡©é žå¡© âŠâŠïŒïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ33ïœ ä¹³ ç³ âŠâŠ75ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ30ïœ ããããã·ãããã«ã»ã«ããŒã¹ âŠâŠïŒïœ 軜質ç¡æ°Žã±ã€é ž âŠâŠïŒïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠïŒïœ åžžæ³ã«åŸã€ãŠãäžèšåæåãæ··åããé¡ç²ç¶ãš
ããå§çž®æåããŠïŒé 150mgã®é è¯1000é ã調補
ããã次ãã§ãããããã·ãããã«ã¡ãã«ã»ã«ã
ãŒã¹ãã¿ã«ã¯ãé žåãã¿ã³ããã³ãœã«ãã¿ã³èèª
é žãšã¹ãã«ãçšããåžžæ³ã«åŸã€ãŠå€ç®ãæœããã€
ã«ã ã³ãŒãã€ã³ã°é ãšããã å®æœäŸ ïŒ ã«ãã»ã«å€ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžå¡©é žå¡© âŠâŠ10ïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ49ïœ ä¹³ ç³ âŠâŠ15ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ25ïœ ã¿ã«ã¯ âŠâŠ0.5ïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠ0.5ïœ åžžæ³ã«åŸã€ãŠãäžèšåæåãæ··åããé¡ç²ç¶ãš
ãããã®ãã«ãã»ã«1000åã«å ãŠãããïŒå100
mgã®ã«ãã»ã«å€ã調補ããã å®æœäŸ ïŒ é å€ ïŒâïŒïŒâïœâããã«âïŒâããã©ãžãã«ïŒâ
ïŒâããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©
âŠâŠ10ïœ ããŠã¢ãã³ã·ãã³ãã³ âŠâŠ27ïœ çµæ¶ã»ã«ããŒã¹ âŠâŠ40ïœ ããããã·ãããã«ã»ã«ããŒã¹ âŠâŠ20ïœ è»œè³ªç¡æ°Žã±ã€é ž âŠâŠïŒïœ ã¹ãã¢ãªã³é žãã°ãã·ãŠã âŠâŠïŒïœ äžèšåæåãæ··åããçŽæ¥æé æ³ã«ããå§çž®æ
åããŠïŒé 100mgã®é è¯1000é ã調補ããã次ã
ã§ãããããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ãã¿ã«
ã¯ãé žåãã¿ã³ããã³ãœã«ãã¿ã³èèªé žãšã¹ãã«
ãçšããåžžæ³ã«åŸã€ãŠå€ç®ãæœããã€ã«ã ã³ãŒã
ã€ã³ã°é ãšããã å®æœäŸ ïŒ ïŒâããšãã«âïŒâïŒïŒâïœâãããã«âïŒâ
ããã©ãžãã«ïŒãããªã³ã»ãžå¡©é žå¡©ãŸãã¯ïŒâ
ïŒïŒâã¢ãªã«âïŒâããã©ãžãã«ïŒâïŒâããšã
ã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©ãçšããå®æœäŸïŒïŒ
ïŒãŸãã¯ïŒãšåæ§ã«åŠçããŠãé å€ãŸãã¯ã«ãã»
ã«å€ãåŸãã å®æœäŸ ïŒ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ ïŒâã¯ããâïŒâããšãã«ãããªã³2.0ïœãã
ã³ïŒâãšãã«ããã©ãžã³2.7ïœããã«ãšã³15mlã«
å ãã10æéå ç±éæµããããå·åŸãæ°Žãå ãã
é ¢é žãšãã«ã§æœåºããææ©å±€ãç¡æ°Žç¡«é žãããªãŠ
ã ã§ä¹Ÿç¥ããã溶åªãæžå§äžã«çå»ããæ®æž£ãã¯
ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«25ïœãçšããŠ
ã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ããæåã«æº¶åºã
ãéšåãæšãŠãç¶ããŠæº¶åºããéšåãéããŠç®ç
ç©2.3ïœïŒïŒåç87ïŒ ïŒãåŸããèç¹ 87ã88â ãã®éé¢å¡©åºããšã¿ããŒã«æ§å¡©é žã§åŠçããŠå¡©
é žå¡©ãšãªãããšã¿ããŒã«ããåçµæ¶ããŠç®çç©ã®
ãžå¡©é žå¡©ãåŸããèç¹ 225ã230â å®æœäŸ ïŒ ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³ ïŒâã¯ããâïŒâããšãã«ãããªã³4.0ïœãã
ã³ç¡æ°Žããã©ãžã³8.0ïœããã«ãšã³ïŒmlã«å ãã
ïŒæéå ç±éæµããããå·åŸãæ°Žãå ããé ¢é žãš
ãã«ã§æœåºããææ©å±€ãæ°ŽæŽãç¡æ°Žç¡«é žãããªãŠ
ã ã§ä¹Ÿç¥ããã溶åªãæžå§äžã«çå»ããæ®æž£ãã¯
ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«40ïœãçšããŠ
ã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ããæåã«æº¶åºã
ãéšåãæšãŠãç¶ããŠæº¶åºããéšåãéãããšãŒ
ãã«ããåçµæ¶ããŠç®çç©4.4ïœïŒåç92ïŒ ïŒã
åŸããèç¹ 133ã134â å®æœäŸ ïŒ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ ïŒâããšãã«âïŒâïŒïŒâããã©ãžãã«ïŒãã
ãªã³3.0ïœããšãŠåãšãã«1.9ïœããã³çé žãããª
ãŠã 1.1ïœãã¡ãã«ãšãã«ã±ãã³30mlã«å ããæ¹
æäž12æéå ç±éæµãããã次ãã§æžå§äžã«æ¿çž®
ããæ®æž£ã«æ°Žãå ããé ¢é žãšãã«ã§æœåºããææ©
å±€ãç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããã溶åªã®çå»
åŸãæ®æž£ãã¯ãããã«ã ã«æº¶è§£ãããã·ãªã«ã²ã«
30ïœãçšããŠã«ã©ã ã¯ãããã°ã©ãã€ãŒãè¡ãã
æåã«æº¶åºããéšåãéããŠç®çç©2.8ïœïŒåç
85ïŒ ïŒãåŸãã èç¹ 87ã88â å®æœäŸïŒïŒïŒãšåæ§ã«åå¿ã»åŠçããŠæ¬¡ã®åå
ç©ãåŸãã ïŒâããšãã«âïŒâïŒïŒâïœâãããã«âïŒâ
ããã©ãžãã«ïŒãããªã³ã»ãžå¡©é žå¡© èç¹ 225ã230â ïŒâïŒïŒâïœâããã«âïŒâããã©ãžãã«ïŒâ
ïŒâããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡© èç¹ 167ã168â ïŒâïŒïŒâã¢ãªã«âïŒâããã©ãžãã«ïŒâïŒâ
ããšãã«ãããªã³ã»ãžãã¬ã€ã³é žå¡©èç¹ 179ã
181âã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ïŒåŒäžãã¯ççŽ ååæ°ïŒãïŒã®äœçŽã¢ã«ãã«
åºãŸãã¯ã¢ãªã«åºãæå³ãããïŒ ã§è¡šããããïŒâïŒïŒâããã©ãžãã«ïŒâïŒâã
ãšãã«ãããªã³èªå°äœããã³ãã®çççã«èš±å®¹ã
ããå¡©é¡ã ïŒ ïŒâïŒïŒâãšãã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ããã³ãã®çççã«èš±å®¹ãã
ãå¡©é¡ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åå
ç©ã ïŒ ïŒâããšãã«âïŒâïŒïŒâïœâãããã«âïŒ
âããã©ãžãã«ïŒãããªã³ããã³ãã®çççã«èš±
容ãããå¡©é¡ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
ååç©ã ïŒ ïŒâïŒïŒâïœâããã«âïŒâããã©ãžãã«ïŒ
âïŒâããšãã«ãããªã³ããã³ãã®çççã«èš±å®¹
ãããå¡©é¡ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å
åç©ã ïŒ ïŒâïŒïŒâã¢ãªã«âïŒâããã©ãžãã«ïŒâïŒ
âããšãã«ãããªã³ããã³ãã®çççã«èš±å®¹ãã
ãå¡©é¡ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åå
ç©ã ïŒ äžè¬åŒ ïŒåŒäžãã¯ççŽ ååæ°ïŒãïŒã®äœçŽã¢ã«ãã«
åºãŸãã¯ã¢ãªã«åºãæå³ãããïŒ ã§è¡šããããïŒâïŒïŒâããã©ãžãã«ïŒâïŒâã
ãšãã«ãããªã³èªå°äœãŸãã¯ãã®çççã«èš±å®¹ã
ããå¡©ãäž»æåãšããæãã€å€ã ïŒ äž»æåãïŒâïŒïŒâãšãã«âïŒâããã©ãžã
ã«ïŒâïŒâããšãã«ãããªã³ãŸãã¯ãã®çççã«
蚱容ãããå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
æãã€å€ã ïŒ äž»æåãïŒâããšãã«âïŒâïŒïŒâïœâãã
ãã«âïŒâããã©ãžãã«ïŒãããªã³ãŸãã¯ãã®ç
ççã«èš±å®¹ãããå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æãã€å€ã ïŒ äž»æåãïŒâïŒïŒâïœâããã«âïŒâããã©
ãžãã«ïŒâïŒâããšãã«ãããªã³ãŸãã¯ãã®çç
çã«èš±å®¹ãããå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®æãã€å€ã ïŒïŒ äž»æåãïŒâïŒïŒâã¢ãªã«âïŒâããã©ãž
ãã«ïŒâïŒâããšãã«ãããªã³ãŸãã¯ãã®ççç
ã«èš±å®¹ãããå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®æãã€å€ã
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3702978A JPS54128588A (en) | 1978-03-29 | 1978-03-29 | Antidepressive drugs consisting mainly of 2-(1-piperazinyl)- 4-phenylquinoline |
| US06/022,779 US4237135A (en) | 1978-03-29 | 1979-03-22 | 2-(4-Ethyl-1-piperazinyl)-4-phenylquinoline, process for preparation thereof, and composition thereof |
| GB7910802A GB2017698B (en) | 1978-03-29 | 1979-03-28 | 2-(4-ethyl-1-piperazinyl)-4-phenylquinoline and pharmaceutical compositions thereof |
| FR7907932A FR2421173A1 (fr) | 1978-03-29 | 1979-03-29 | 2-(4-ethylpiperazino)-4-phenylquinoleine et ses sels, utiles notamment comme antidepresseurs, et leur procede de preparation |
| IT67658/79A IT1121456B (it) | 1978-03-29 | 1979-03-29 | 2 4 etil i pipera inil 4 fenilchinoline procedimento per la loro preparazione e composizioni farmaceutiche contenenti tali composti |
| DE19792912414 DE2912414A1 (de) | 1978-03-29 | 1979-03-29 | 2-(4-aethyl-1-piperazinyl)-4-phenylchinolin und dessen salze mit saeuren, verfahren zu ihrer herstellung und ihre verwendung als antidepressive wirkstoffe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3702978A JPS54128588A (en) | 1978-03-29 | 1978-03-29 | Antidepressive drugs consisting mainly of 2-(1-piperazinyl)- 4-phenylquinoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54128588A JPS54128588A (en) | 1979-10-05 |
| JPS6344749B2 true JPS6344749B2 (ja) | 1988-09-06 |
Family
ID=12486204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3702978A Granted JPS54128588A (en) | 1978-03-29 | 1978-03-29 | Antidepressive drugs consisting mainly of 2-(1-piperazinyl)- 4-phenylquinoline |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4237135A (ja) |
| JP (1) | JPS54128588A (ja) |
| DE (1) | DE2912414A1 (ja) |
| FR (1) | FR2421173A1 (ja) |
| GB (1) | GB2017698B (ja) |
| IT (1) | IT1121456B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
| JPS59222418A (ja) * | 1983-05-31 | 1984-12-14 | Dainippon Pharmaceut Co Ltd | æ朰çå€ |
| US4677107A (en) * | 1983-05-31 | 1987-06-30 | Dainippon Pharmaceutical Co., Ltd. | Anti-peptic ulcer agent |
| KR860700352A (ko) * | 1984-11-27 | 1986-10-06 | íì§ìëŒ ëë¯žì€ | 2--(1-íŒíëŒì§ë)-4-ì¹í íëíŽë늰 ì ë첎ì ê·ž ìŒì ì ì¡°ë°©ë² |
| FR2637591B1 (fr) * | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
| DK0385237T3 (da) * | 1989-03-03 | 1994-07-25 | Dainippon Pharmaceutical Co | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk prÊparat indeholdende dem |
| CA2144669A1 (en) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542785A (en) * | 1967-05-15 | 1970-11-24 | Ciba Geigy Corp | 2-hydroxy-4-aryl-quinolines |
| US3576809A (en) * | 1968-05-06 | 1971-04-27 | Miles Lab | 2-substituted derivatives of 6-methoxyquinoline |
| US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
| US3737540A (en) * | 1972-02-14 | 1973-06-05 | Miles Lab | Composition for suppressing the tremor of parkinson's syndrome |
-
1978
- 1978-03-29 JP JP3702978A patent/JPS54128588A/ja active Granted
-
1979
- 1979-03-22 US US06/022,779 patent/US4237135A/en not_active Expired - Lifetime
- 1979-03-28 GB GB7910802A patent/GB2017698B/en not_active Expired
- 1979-03-29 IT IT67658/79A patent/IT1121456B/it active
- 1979-03-29 FR FR7907932A patent/FR2421173A1/fr active Granted
- 1979-03-29 DE DE19792912414 patent/DE2912414A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE2912414A1 (de) | 1979-10-04 |
| FR2421173A1 (fr) | 1979-10-26 |
| GB2017698A (en) | 1979-10-10 |
| IT7967658A0 (it) | 1979-03-29 |
| DE2912414C2 (ja) | 1988-03-17 |
| JPS54128588A (en) | 1979-10-05 |
| FR2421173B1 (ja) | 1983-01-28 |
| IT1121456B (it) | 1986-04-02 |
| US4237135A (en) | 1980-12-02 |
| GB2017698B (en) | 1982-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3148253B2 (ja) | ãã³ãŸããªã«èªå°äœé¡åã³ãããã®çšé | |
| JP2008519083A (ja) | ã¢ãããããŸãªã³ååç© | |
| JPH0224821B2 (ja) | ||
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| JP6755950B2 (ja) | ã©ã¯ã¿ã ååç©èªå°äœããã³ãã®å¿çš | |
| KR850000216B1 (ko) | íŒíëŒì§ ì ë첎ì ì ì¡°ë°©ë² | |
| HU196195B (en) | Process for producing 1,4-disubstituted piperazine derivatives and pharmaceuticals comprising the compounds | |
| JPS6230780A (ja) | ïŒïŒïŒâããããªãžã³èªå°äœåã³ãããå«æããè¬å€ | |
| JPS62273969A (ja) | ïŒïŒïŒâäºçœ®æããã©ãžã³èªå°äœããããå«ãè¬å€çµæç©ããã³ãã®è£œé æ¹æ³ | |
| JPS6344749B2 (ja) | ||
| JPH037257A (ja) | ããªãžã³èªå°äœåã³ãããæå¹æåãšããå粟ç¥å€ | |
| JPS63290868A (ja) | ãžã±ãããã©ãžã³èªå°äœããã³ãã®å¡©é¡ | |
| JP2018035186A (ja) | ãã³ãŸãã¢ãŸãã³ååç©ãå«ãè£œå€ | |
| DK166584B1 (da) | Substituerede 4-benzyl-1h-imidazoler, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende dem | |
| JP3193789B2 (ja) | ãã¢ãžã¢ãžãã³é¡ | |
| JP2726999B2 (ja) | ã€ãããŸïŒ»ïŒïŒïŒâïœïŒœãã³ãŸãã¢ãŸãŒã«èªå°äœåã³è©²ååç©ãæå¹æåãšããæ朰çå€ | |
| SK2722002A3 (en) | Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia | |
| DK159435B (da) | Analogifremgangsmaade til fremstilling af 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)benzoesyrederivater eller et farmaceutisk acceptabelt syreadditionssalt deraf | |
| JP6786599B2 (ja) | çž®åè€çŽ ç°ååç©èªå°äœããã³ãã®å¿çš | |
| DK158944B (da) | Analogifremgangsmaade til fremstilling af substituerede methylimidazolforbindelser | |
| JPH0377191B2 (ja) | ||
| JPH01149792A (ja) | ïŒâã¯ããâïŒâããããã·âïŒâã¡ãã«ââïŒïŒâããªãžã«ïŒâïŒïŒšâããšããïŒïŒïŒâïœ ãâïŒïŒïŒâãã¢ãžã³âïŒâã«ã«ãããµããâïŒïŒïŒâãžãªãã·ãã®ãšããŒã«ãšãŒãã«ããã®è£œé æ¹æ³ããã³çšé | |
| JPS61267555A (ja) | ãããªã³èªå°äœåã³ãããæå¹æåãšããæ朰çå€ | |
| JPH04312585A (ja) | ãããªãžã³èªå°äœ | |
| JP2678768B2 (ja) | ããã©ãããã€ãããŸïŒ»ïŒïŒïŒâïœïŒœãã³ãŸãã¢ãŸãŒã«èªå°äœåã³è©²ååç©ãæå¹æåãšããæ朰çå€ |